



#9c 12-02

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Kola, et al.

Appl. No.

09/786,043

Filed

August 13, 2001

For

NOVEL THERAPEUTIC

MOLECULES AND USES

THEREFOR

Examiner

Angell, J.E.

Group Art Unit 1635

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: United States Patent and Trademark Office, PO BOX 2327, Arlington, VA 22202, on

July 26, 2002

(Date)

Sam K. Tahmassebi, Reg. No. 45,151

RESPONSE TO RESTRICTION REQUIREMENT

RECEIVED

AUG 0 6 2002

United States Patent and Trademark Office PO BOX 2327 Arlington, VA 22202

TECH CENTER 1600/2900

Dear Sir:

In response to the Restriction Requirement of February 27, 2002, please enter the following amendments and consider the following remarks.

08/01/2002 6WDRDDF1 00000055 09786043 08/01/2002 GWDRDDF1 0000055 0978888300 OP -720.00 DF

AMENDMENTS

IN THE CLAIMS:

Please amend Claims 102-113 and 115-123 to read as follows:

An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a nucleotide sequence encoding, an amino acid sequence substantially as set forth in SEQ ID NO:2 or a derivative homologue or mimetic thereof or having at least about 45% or greater similarity to at least 10 contiguous amino acids in SEQ ID NO:2.

Ò8/02/2002 GWORDOF1 00000035 09786043

01 FC:218

720.00 OP

-1-